Detection of RBM 15-MKL 1 Fusion Was Useful for Diagnosis and Monitoring of Minimal Residual Disease in Infant Acute Megakaryoblastic Leukemia

Departments of aPediatrics, fPediatric Hematology/Oncology, dDivision of Medical Support, Okayama University Hospital, Okayama 700-8558, Japan, bDepartment of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima 730-8619, Japan, cDepartment of Pharmacology, Meijo University, Nagoya 468-8503, Japan, eDepartment of Laboratory Medicine, National Hospital Organization Okayama Medical Center, Okayama 701-1154, Japan

[1]  Y. Hayashi,et al.  High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group , 2012, International Journal of Hematology.

[2]  I. Buño,et al.  Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  Hirotoshi Sakaguchi,et al.  Molecular lesions in childhood and adult acute megakaryoblastic leukaemia , 2012, British journal of haematology.

[4]  M. Teixeira,et al.  Acute megakaryoblastic leukemia with a four‐way variant translocation originating the RBM15–MKL1 fusion gene , 2011, Pediatric blood & cancer.

[5]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[6]  Martin Klabusay,et al.  Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. , 2009, Experimental hematology.

[7]  A. Orazi.  Histopathology in the Diagnosis and Classification of Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Myelodysplastic/Myeloproliferative Diseases , 2007, Pathobiology.

[8]  G. Schuurhuis,et al.  MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia , 2004, Leukemia.

[9]  R. Berger,et al.  A novel real-time RT-PCR assay for quantification of OTT-MAL fusion transcript reliable for diagnosis of t(1;22) and minimal residual disease (MRD) detection , 2003, Leukemia.

[10]  G. Flandrin,et al.  Acute Megakaryoblastic Leukaemia: A National Clinical and Biological Study of 53 Adult and Childhood Cases by the Groupe Français d'Hématologie Cellulaire (GFHC) , 2003, Leukemia & lymphoma.

[11]  Dean Nizetic,et al.  Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia , 2001, Nature Genetics.

[12]  Nicole Dastugue,et al.  Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  N. Heerema,et al.  Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group , 2000, Leukemia.

[14]  A. Pappo,et al.  The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. , 1991, Blood.